Principia Biopharma Inc (PRNB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Principia Biopharma Inc (PRNB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11223
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Principia Biopharma Inc (Principia Biopharma) is a clinical stage biopharmaceutical company that designs and develops oral small molecule drug therapies for immune disorders and cancer. The company, through its proprietary Tailored Covalency platform, develops a portfolio of drug candidates such as PRN1008, PRN2246 and PRN1371. PRN1008, under Phase 3 initiation for pemphigus vulgaris, an orphan autoimmune disease, and Phase 2 trial for immune thrombocytopenic purpura, is a reversible covalent BTK inhibitor. PRN2246, which crosses the blood-brain barrier, is under Phase 1 clinical trial as an oral therapy to treat autoimmunity and neuro-inflammatory diseases. The PRN1371 candidate, under Phase 1 trial, is used in treating bladder cancer and solid tumors. Principia Biopharma is headquartered in South San Francisco, California, the US.

Principia Biopharma Inc (PRNB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Principia Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Principia Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Principia Biopharma Raises USD15.2 Million in Venture Funding 11
Principia Biopharma Raises US$50 Million In Series B Venture Financing 12
Principia Biopharma Raises Additional US$13 Million In Series A Financing 14
Private Equity 16
Principia Biopharma Raises USD50 Million in Offering of Series C Preferred Stock 16
Partnerships 17
AbbVie and Principia Biopharma Enter into Agreement 17
Guardant Health Enters into Agreement with Principia Biopharma 18
Licensing Agreements 19
Sanofi Amends Licensing Agreement with Principia Biopharma 19
Equity Offering 20
Principia Biopharma Raises USD122.2 Million in IPO of Shares 20
Principia Biopharma Inc – Key Competitors 22
Principia Biopharma Inc – Key Employees 23
Principia Biopharma Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Nov 06, 2018: Principia Biopharma reports third quarter financial results 25
Corporate Communications 26
Oct 24, 2018: Principia Biopharma appoints Dolca Thomas, M.D. as Chief Medical Officer 26
Clinical Trials 27
Jul 26, 2018: Principia confirms human CNS exposure and good tolerability of oral BTK inhibitor PRN2246 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Principia Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Principia Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Principia Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Principia Biopharma Raises USD15.2 Million in Venture Funding 11
Principia Biopharma Raises US$50 Million In Series B Venture Financing 12
Principia Biopharma Raises Additional US$13 Million In Series A Financing 14
Principia Biopharma Raises USD50 Million in Offering of Series C Preferred Stock 16
AbbVie and Principia Biopharma Enter into Agreement 17
Guardant Health Enters into Agreement with Principia Biopharma 18
Sanofi Amends Licensing Agreement with Principia Biopharma 19
Principia Biopharma Raises USD122.2 Million in IPO of Shares 20
Principia Biopharma Inc, Key Competitors 22
Principia Biopharma Inc, Key Employees 23

List of Figures
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Principia Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Principia Biopharma Inc (PRNB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Efore Oyj (EFO1V):企業の財務・戦略的SWOT分析
    Efore Oyj (EFO1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • G&W Electric Company:企業の戦略的SWOT分析
    G&W Electric Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Logicalis Group Ltd:企業の戦略的SWOT分析
    Logicalis Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Ryerson Holding Corp:戦略・SWOT・企業財務分析
    Ryerson Holding Corp - Strategy, SWOT and Corporate Finance Report Summary Ryerson Holding Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Swelect Energy Systems Ltd (SWELECTES):電力:M&Aディール及び事業提携情報
    Summary Swelect Energy Systems Ltd (SESL), formerly Numeric Power Systems Ltd is an energy company that manufactures and markets renewable energy products and iron and steel products. The company’s renewable energy products include solar pv modules, solar inverter, solar water pump and energy effici …
  • Cipla Ltd (CIPLA):製薬・医療:M&Aディール及び事業提携情報
    Summary Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetologi …
  • Standard Chartered Private Bank:企業の戦略・SWOT・財務情報
    Standard Chartered Private Bank - Strategy, SWOT and Corporate Finance Report Summary Standard Chartered Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Ergon Inc:企業の戦略的SWOT分析
    Ergon Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Presence Health:企業の戦略的SWOT分析
    Presence Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Liberty Insurance Berhad:企業の戦略・SWOT・財務情報
    Liberty Insurance Berhad - Strategy, SWOT and Corporate Finance Report Summary Liberty Insurance Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • EnergySolutions LLC:企業の戦略的SWOT分析
    EnergySolutions LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • AngloGold Ashanti Ltd:企業のM&A・事業提携・投資動向
    AngloGold Ashanti Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AngloGold Ashanti Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Zeltiq Aesthetics Inc (ZLTQ):企業の財務・戦略的SWOT分析
    Summary Zeltiq Aesthetics Inc (Zeltiq), formerly Juniper Medical Inc, a subsidiary of Allergan Plc, is a medical technology company that develops and commercializes non-invasive products for the reduction of fat, selectively. The company offers CoolSculpting system, which uses proprietary controlled …
  • Siemens Healthcare GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Siemens Healthcare GmbH d/b/a Siemens Healthineers, a subsidiary of Siemens AG, is a global medical device company that designs, develops, manufactures and distributes medical devices and technologies for diagnostic markets. Its major products include healthcare IT and medical infrastructure …
  • Nippon Yusen Kabushiki Kaisha (9101):石油・ガス:M&Aディール及び事業提携情報
    Summary Nippon Yusen Kabushiki Kaisha (NYK) is a logistics company. It transports crude oil and allied products. The company provides ocean, land, and air transport services for the transportation of petroleum products, liquid products and dry bulk products. Its portfolio includes linear trade, air …
  • Rite Aid Corporation:企業の戦略・SWOT・財務分析
    Rite Aid Corporation - Strategy, SWOT and Corporate Finance Report Summary Rite Aid Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Exact Sciences Corp (EXAS):企業の製品パイプライン分析2018
    Summary Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the early detection and prevention of various types of cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the …
  • Siemens Healthineers.:戦略・SWOT・企業財務分析
    Siemens Healthineers. - Strategy, SWOT and Corporate Finance Report Summary Siemens Healthineers. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • FirstGroup plc (FGP):企業の財務・戦略的SWOT分析
    FirstGroup plc (FGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Metinvest BV:企業の戦略・SWOT・財務情報
    Metinvest BV - Strategy, SWOT and Corporate Finance Report Summary Metinvest BV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆